Skip to Content
Living with HIV? Check out the patient's guide to HIV

Abacavir / lamivudine Pregnancy and Breastfeeding Warnings

Abacavir / lamivudine is also known as: Epzicom

Abacavir / lamivudine Pregnancy Warnings

Abacavir-lamivudine has been assigned to pregnancy category C by the FDA. High-dose studies with abacavir in rats have revealed evidence of embryonic and fetal toxicity, including developmental toxicity, fetal anasarca, skeletal malformations, and increased incidence of stillbirth. High-dose studies with lamivudine in rats have failed to reveal evidence of fetotoxicity. However, there is some indication of early embryolethality in rabbit studies using doses proportional to normal human dosages. There are no controlled data in human pregnancy. Abacavir-lamivudine is only recommended for use during pregnancy when benefit outweighs risk. To monitor fetal outcomes of pregnant women exposed to abacavir-lamivudine, an Antiretroviral Pregnancy Registry has been established. Healthcare providers are encouraged to register patients by calling 1-800-258-4263 (USA).

See references

Abacavir / lamivudine Breastfeeding Warnings

There are no data on the excretion of abacavir into human milk. It is excreted into the milk of lactating rats. Lamivudine is excreted into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, mothers should not breast-feed during abacavir-lamivudine therapy. In addition, HIV-infected mothers should not breast-feed their infants due to the risk of transmission of HIV via breast milk.

See references

References for pregnancy information

  1. "Product Information. Epzicom (abacavir-lamivudine)." GlaxoSmithKline, Research Triangle Park, NC.

References for breastfeeding information

  1. "Product Information. Epzicom (abacavir-lamivudine)." GlaxoSmithKline, Research Triangle Park, NC.
  2. "Infant feeding and transmission of human immunodeficiency virus in the United States." Pediatrics 131 (2013): 391-6
  3. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. National Institute of Health "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL:" ([2011 Sep 14]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.